RZLT
Rezolute·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 0
Consensus Rating "Strong Buy"
Ample Liquidity
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About RZLT
Rezolute, Inc.
A clinical-stage biopharmaceutical company that develops drug therapies for the treatment of metabolic diseaes
275 Shoreline Drive, Suite 500, Redwood City, California 94065
--
Rezolute, Inc., was incorporated in Delaware in 2010 and re-incorporated in Nevada in June 2021. The Company is an advanced rare disease company focused on significantly improving the prognosis of patients with hypoglycemia caused by hyperinsulinemia (" HI "). The company's main clinical asset, ersodetug, is a potential treatment for hypoglycemia caused by many forms of hyperinsulinemia.
Company Financials
EPS
RZLT has released its 2026 Q1 earnings. EPS was reported at -0.18, versus the expected -0.26, beating expectations. The chart below visualizes how RZLT has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
